Europe-based Kurma Life Sciences Partners has hired Vanessa Malier as a partner. Previously, Malier worked at Ipsen where she was vice president of R&D strategic planning. KLS is a VC firm that focuses on healthcare and biotechnology.
Paris, September 24th, 2013
Kurma Life Sciences Partners announces that Vanessa Malier joins as Partner
Vanessa joins today Kurma Life Sciences Partners as Partner, bringing 15 years of experience in Biotech and pharmaceutical industry, in business development, global strategic marketing, project and portfolio management. Prior to joining Kurma, Vanessa was Vice President, R&D Strategic Planning at Ipsen.
Vanessa, 40 years old, graduated from Ecole Normale Superieure (Cachan) in Biology and from Pasteur Institute (Paris) in Immunology.
Vanessa started her career in 2008 at CDC Innovation, a venture capital firm as Analyst, and then moved to a California-based start-up “Drug Abuse Sciences” as Business Development Manager. In 2003, Vanessa joined Ipsen as Strategic Advisor to the CEO, and was appointed in 2005 as Product Leader for febuxostat (Adenuric®), which received EMA approval in 2008. In 2009, Vanessa was appointed as Senior Director, Business Development Oncology and led the acquisition of a phase III asset.
Vanessa will add a strong operational background to the Team, and will reinforce Kurma Life Sciences Partners positioning as an active investor operating in the field of life sciences in Europe, few months after the launch of Kurma Biofund II, the first Venture Capital fund dedicated to financing innovation in the rare diseases space.
About Kurma Life Sciences Partners – www.kls-partners.com
Founded in July 2009, Kurma Life Sciences Partners is a key European player in the financing of Innovation in Healthcare and Biotechnology, from pre-seed to growth capital, notably through Kurma Biofund I and II, and strategic partnerships with prestigious European research and medical institutions.